BioAtla BCAB
OTC BCAB
$1.75 -0.05 (-2.78%)
At close: Nov 11, 2026 · 4:00 PM EST

BioAtla (BCAB) Price to Sales (2020 - 2026)

Updated

BioAtla's (BCAB) Price to Sales stood at 0.81 in Q2 2026, down 99.2% from 97.70 a year earlier.

Analysis

BioAtla (BCAB) Price to Sales (2020 - 2026) Analysis & Trends

For FY2025, BioAtla's Price to Sales came in at 901.19, up 477.4% from FY2024.

  • Across earlier years, Price to Sales came in at 156.08 in FY2024 and 140547.79 in FY2021 (-54.9%).
  • The Q2 2026 figure is the lowest quarterly Price to Sales in data going back to Q4 2020.
  • On a year-over-year basis, Price to Sales rose in 1 of the last five quarters, with growth averaging 36.4%.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 BioAtla 2.99 Mn -15.95 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.81
Dec 31, 2025 18.02
Sep 30, 2025 3.68
Jun 30, 2025 1.95
Dec 31, 2024 2.89
Sep 30, 2024 7.15
Jun 30, 2024 73.56
Sep 30, 2023 325.77
Dec 31, 2021 2,810.96
Sep 30, 2021 4,144.03
Jun 30, 2021 3,423.81
Mar 31, 2021 4,810.59
Dec 31, 2020 6,228.68
API Access

BioAtla Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=BCAB&period=max&api_key=YOUR_API_KEY